Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors

August 20, 2019
Arbutus Biopharma Corp.

WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019. “We are pleased to welcome Dr. Cheng to the Arbutus Board,” said Dr. Frank Torti, Chairman of the Arbutus Board … Continue reading Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors

DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering

August 19, 2019
DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced the pricing of an underwritten public offering of 6,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in … Continue reading DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering

DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

August 13, 2019
DelMar Pharmaceuticals, Inc.

August 13, 2019 53% of assessed patients have achieved a complete response; 41% have achieved stable disease VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 13, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, provided an update on the first 20 patients … Continue reading DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction

August 9, 2019
Neoleukin Therapeutics, Inc.

Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc.(“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP). Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” … Continue reading Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction

Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

August 7, 2019
Aquinox Pharmaceuticals Inc.

SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc.(“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), today announced that Jonathan G. Drachman, M.D., CEO, of Neoleukin, will present a corporate overview at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Thursday, August 8th, 2019 at 3:00 p.m. Eastern. A webcast of … Continue reading Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

August 6, 2019

Anticipate Testing of New Pediatric Formulations of XEN496 and XEN901 in Adults in Third Quarter,  Followed by IND Submissions to Initiate Pediatric Clinical Trials in   KCNQ2 and SCN8A Developmental and Epileptic Encephalopathies Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 06, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage … Continue reading Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement

Aquinox Pharmaceuticals Inc.

Sophisticated computational platform enables new class of de novo protein therapeutics Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable therapeutic index Conference call on August 6, 2019 at 9 a.m. EDT / 6 a.m. PDT VANCOUVER, British Columbia and SEATTLE, Aug. 06, 2019 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP) and Neoleukin Therapeutics, Inc. (“Neoleukin”), a privately held biopharmaceutical company utilizing … Continue reading Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement

Arbutus to Participate at Wedbush PacGrow Healthcare Conference

Arbutus Biopharma Corp.

WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 10:55 am ET in New York. A live webcast of the fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.  A replay … Continue reading Arbutus to Participate at Wedbush PacGrow Healthcare Conference

New Form 10-Q for Aquinox Pharmaceuticals, Inc.

August 1, 2019
Aquinox Pharmaceuticals, Inc.

August 1, 2019 A Form 10-Q has been filed with the United States Securities and Exchange Commission. View this filing → Or click here to view all filings.

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update

July 31, 2019
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, August 6, 2019. Xenon management will host a conference call and live audio webcast at … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update